Pathophysiology of the metabolic syndrome Emma McCracken, MRCP (UK), Monica Monaghan, MBBCh, BAO, BSc, PhD, MRCP (UK), Shiva Sreenivasan, FRCP Edin, FRCP Clinics in Dermatology Volume 36, Issue 1, Pages 14-20 (January 2018) DOI: 10.1016/j.clindermatol.2017.09.004 Copyright © 2017 Terms and Conditions
Fig. 1 Schematic diagram of the mechanism of action of insulin on intracellular signaling pathways. GLUT4, glucose transporter 4 (an insulin transporter regulated by insulin); GSK3, glycogen synthase kinase 3; PI3K, phosphoinositide 3-kinase; PKA, protein kinase A. Clinics in Dermatology 2018 36, 14-20DOI: (10.1016/j.clindermatol.2017.09.004) Copyright © 2017 Terms and Conditions
Fig. 2 NADPH Nicotinamide adenine dinucleotide phosphate; IL-6 Interleukin-6; TNF-α Tumour necrosis factor alpha; PAI-1 Plasminogen activator inhibitor-1; OxLDL Oxidized low density lipoprotein. Schematic diagram of the role of inflammatory and oxidative mediators in the pathogenesis of atherosclerosis in the metabolic syndrome. Clinics in Dermatology 2018 36, 14-20DOI: (10.1016/j.clindermatol.2017.09.004) Copyright © 2017 Terms and Conditions